Diagnostic yield of a novel tracer 68Ga-citrate in sarcoidosis patients 68Ga-citrate PET/CT in sarcoidosis
Main Article Content
Keywords
sarcoidosis, 68Ga-citrate, diagnosis, 18FDG, PET/CT, malignancy
Abstract
Abstract
Background: Sarcoidosis is a granulomatous disease of unknown origin. Conventional laboratory and imaging modalities may lead to equivocal conclusions for sarcoidosis diagnosis. 68Ga-citrate PET/CT has been utilized in the diagnosis of inflammatory and infectious diseases due to its beter performance.
Aims: This study was designed to determine the clinical trenchancy of 68Ga-citrate in sarcoidosis patients as an alternative tracer that binds to the somtastotin receptors of the inflammatory cells in sarcoid granulomas because current laboratory modalities may occasionally lack accuracy for sarcoidosis diagnosis. Conventional criteria including clinical, laboratory, radiologic modalities, and 18F-FDG PET/CT were compared with the 68Ga-citrate PET/CT to evaluate the diagnostic yield in sarcoidosis.
Methods: Forty-four sarcoidosis patients were include in the study. Conventional laboratory and imaging modalities were done in 44 while 68Ga-citrate PET/CT and 18F-FDG-PET/CT were performed in 22 patients. The three modalities were compared with in regard to granulomatous activity evaluation, extrapulmonary organ involvement, and identification of coexistent malignant disease.
Results: 68Ga-citrate PET/CT revealed a significantly higher diagnostic yield for sarcoidosis compared to conventional laboratory and 18F-FDG-PET/CT imaging modalties. 68Ga-citrate PET/CT revealed 72.7% sensitivity and 68.4% specificity for the detection of granulomatous inflammation in sarcoidosis.
Conclusions: 68Ga-citrate PET/CT was conclusive for activity assessment in sarcoidosis for diagnosis, activity assessment, and identification of extrapulmonary organ involvement. As an innovative novel tracer, 68Ga-citrate identified disease activity, extrapulmonary organ involvement, biopsy sites, and coexistent malignancy due to its chemical properties with a higher statistical diagnostic yield compared to conventional laboratory findings and the PET/CT imaging manifestations in sarcoidosis.
References
2.Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. February (1999). Am J Respir Crit Care Med 160(2):736-55.
3.Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. (1999) Eur Respir J;14(4):735-7.
4.Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. (1999) Sarcoidosis Vasc Diffuse Lung Dis 16(2):149-73.
5.Youssef G, Leung E, Mylonas I, et al. (2012) The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53(2):241-8.
6.Akaike G, Itani M, Shah H, et al. PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations. (2018) RadioGraphics 38:1536–49.
7.Rubini G, Ferrari C, Altini C, et al. (2019) Diagnostic Performance of 18F-FDG PET/CT Semiquantitative Analysis in the Management of Sarcoidosis. Curr Med Imaging Rev 15(1):32-8.
8.Mostard RLM.Verschakelen JA. Van Kroonenburgh MJPG, et al. (2013) Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respiratory Medicine 107: 439–47.
9.Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. (2012) The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 53(10):1543-9.
10.Ambrosini V, Zompatori M, Fasano L, et al. (2013) 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med 38(4):171-7.
11.Sobic-Saranovic D, Artiko V, Obradovic V. (2013) FDG PET imaging in sarcoidosis. Semin Nucl Med. 43(6):404-11.
12.Treglia G, Annunziata S, Sobic-Saranovic D, et al. (2014) The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. Acad Radiol. 21(5):675-84.
13.Slart RHJA, Koopmans KP, van Geel PP, et al. (2017) Somatostatin receptor based hybrid imaging in sarcoidosis. Eur J Hybrid Imaging 1(1):1-5.
14.Sharma S, Singh AD, Sharma SK, et al. (2018) Gallium-68 DOTA-NOC PET/CT as an alternate predictor of disease activity in sarcoidosis. Nucl Med Commun 39(8):768-78.
15.Kamphuis LS, Kwekkeboom DJ, Missotten TO, et al. (2015) Somatostatin receptor scintigraphy patterns in patients with sarcoidosis. Clin Nucl Med 40(12):925-9.
16.Lapa C, Reiter T, Kircher M, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. (2016) Oncotarget 7(47):77807-14.
17.Nobashi T, Nakamoto Y, Kubo T, et al. (2016) The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy. Ann Nucl Med 30(8):544-52.
18.Teirstein AS, Machac J, Almeida O, et al. (2007) Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 132(6):1949-53.
19.Mostard RLM, Vöö S, van Kroonenburgh MJ, et al. (2011) Inflammatory activity assessment by F18FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 105:1917–24.
20.Keijsers RG, Verzijlbergen FJ, van den Bosch JM, et al. (2011) 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 28:123–9.
21.Brudin LH, Valind SO, Rhodes CG, et al. (1994) Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21:297–305.
22.Nishiyama Y, Yamamoto Y, Fukunaga K, et al. (2006) Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47:1571–6.
23.Kaira K, Oriuchi N, Otani Y, et al. (2007) Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 131:1019-27.
24.Tetikkurt C, Yanardag H, Sayman BH, et al. (2020) Diagnostic utility of 68Ga-citrate and 18FDG PET/CT in sarcoidosis patients. Monaldi Arch Chest Dis 23;90(4):729-37.
25.Tetikkurt C, Yanardag H, Sayman H, et al. (2020) Simultaneous use of FDG-18 and 68Ga-citrate PET/CT for the differential diagnosis of sarcoidosis and malignant disease. Monaldi Arch Chest Dis 29;90(3):469-72.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
